ITTO20040124A1 - Nuovi impieghi in terapia di derivati di n-piperidina particolarmente per il trattamento di patologie neurodegenerative - Google Patents

Nuovi impieghi in terapia di derivati di n-piperidina particolarmente per il trattamento di patologie neurodegenerative

Info

Publication number
ITTO20040124A1
ITTO20040124A1 IT000124A ITTO20040124A ITTO20040124A1 IT TO20040124 A1 ITTO20040124 A1 IT TO20040124A1 IT 000124 A IT000124 A IT 000124A IT TO20040124 A ITTO20040124 A IT TO20040124A IT TO20040124 A1 ITTO20040124 A1 IT TO20040124A1
Authority
IT
Italy
Prior art keywords
therapy
treatment
piperidine derivatives
new uses
neurodegenerative pathologies
Prior art date
Application number
IT000124A
Other languages
English (en)
Inventor
Gianfranco Merizzi
Original Assignee
Medestea Internaz Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medestea Internaz Srl filed Critical Medestea Internaz Srl
Priority to IT000124A priority Critical patent/ITTO20040124A1/it
Publication of ITTO20040124A1 publication Critical patent/ITTO20040124A1/it
Priority to PCT/EP2005/001818 priority patent/WO2005084677A1/en
Priority to CA2556383A priority patent/CA2556383C/en
Priority to US10/589,469 priority patent/US8461186B2/en
Priority to CN2005800066332A priority patent/CN1946400B/zh
Priority to ES05715443T priority patent/ES2392846T3/es
Priority to PL05715443T priority patent/PL1727545T3/pl
Priority to EP05715443A priority patent/EP1727545B1/en
Priority to RU2006134643/15A priority patent/RU2377986C2/ru
Priority to JP2007501168A priority patent/JP2007525530A/ja
Priority to BRPI0507817-2A priority patent/BRPI0507817A/pt
Priority to KR1020067020673A priority patent/KR101244799B1/ko
Priority to AU2005218739A priority patent/AU2005218739A1/en
Priority to NO20064426A priority patent/NO20064426L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT000124A 2004-03-01 2004-03-01 Nuovi impieghi in terapia di derivati di n-piperidina particolarmente per il trattamento di patologie neurodegenerative ITTO20040124A1 (it)

Priority Applications (14)

Application Number Priority Date Filing Date Title
IT000124A ITTO20040124A1 (it) 2004-03-01 2004-03-01 Nuovi impieghi in terapia di derivati di n-piperidina particolarmente per il trattamento di patologie neurodegenerative
AU2005218739A AU2005218739A1 (en) 2004-03-01 2005-02-22 Use of N-piperidine derivatives for the treatment of neurodegenerative pathologies
PL05715443T PL1727545T3 (pl) 2004-03-01 2005-02-22 Zastosowanie pochodnych N-piperydyny do leczenia patologii neurodegeneracyjnych
CA2556383A CA2556383C (en) 2004-03-01 2005-02-22 Use of n-piperidine derivatives for the treatment of neurodegenerative pathologies
US10/589,469 US8461186B2 (en) 2004-03-01 2005-02-22 Use of N-piperidine derivatives for the treatment of neurodegenerative pathologies
CN2005800066332A CN1946400B (zh) 2004-03-01 2005-02-22 N-哌啶衍生物用于治疗神经变性疾病的应用
ES05715443T ES2392846T3 (es) 2004-03-01 2005-02-22 Uso de derivados de N-piperidina para el tratamiento de patologías neurodegenerativas
PCT/EP2005/001818 WO2005084677A1 (en) 2004-03-01 2005-02-22 Use of n-piperidine derivatives for the treatment of neurodegenerative pathologies
EP05715443A EP1727545B1 (en) 2004-03-01 2005-02-22 Use of n-piperidine derivatives for the treatment of neurodegenerative pathologies
RU2006134643/15A RU2377986C2 (ru) 2004-03-01 2005-02-22 Применение производных n-пиперидина для лечения нейродегенеративных патологий
JP2007501168A JP2007525530A (ja) 2004-03-01 2005-02-22 神経変性病変の治療におけるｎ−ピペリジン誘導体の使用
BRPI0507817-2A BRPI0507817A (pt) 2004-03-01 2005-02-22 uso de derivados n-piperidina para o tratamento de patologias neurodegenerativas
KR1020067020673A KR101244799B1 (ko) 2004-03-01 2005-02-22 신경퇴행성 병을 치료하기 위한 ｎ-피페리딘 유도체의 용도
NO20064426A NO20064426L (no) 2004-03-01 2006-09-29 Anvendelse av N-piperidinderivater til behandling av neurodegenerative patologier

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000124A ITTO20040124A1 (it) 2004-03-01 2004-03-01 Nuovi impieghi in terapia di derivati di n-piperidina particolarmente per il trattamento di patologie neurodegenerative

Publications (1)

Publication Number Publication Date
ITTO20040124A1 true ITTO20040124A1 (it) 2004-06-01

Family

ID=34917559

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000124A ITTO20040124A1 (it) 2004-03-01 2004-03-01 Nuovi impieghi in terapia di derivati di n-piperidina particolarmente per il trattamento di patologie neurodegenerative

Country Status (14)

Country Link
US (1) US8461186B2 (it)
EP (1) EP1727545B1 (it)
JP (1) JP2007525530A (it)
KR (1) KR101244799B1 (it)
CN (1) CN1946400B (it)
AU (1) AU2005218739A1 (it)
BR (1) BRPI0507817A (it)
CA (1) CA2556383C (it)
ES (1) ES2392846T3 (it)
IT (1) ITTO20040124A1 (it)
NO (1) NO20064426L (it)
PL (1) PL1727545T3 (it)
RU (1) RU2377986C2 (it)
WO (1) WO2005084677A1 (it)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2368937T3 (es) * 2006-01-19 2011-11-23 Medestea Research & Production S.P.A. Uso de composiciones de derivados de n-piperidina para proteger sistemas biológicos.
EP2040694A2 (en) * 2006-07-14 2009-04-01 VIB vzw Use of ppar-alpha agonists to treat skeletal muscle wasting disorders
WO2009023707A1 (en) * 2007-08-14 2009-02-19 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of treating disease involving myelin and/or axonal loss
KR101491763B1 (ko) * 2013-12-19 2015-02-16 대한민국 1-(2-((4-클로로-2-메톡시-5-메칠페닐)아미노)-2-옥소에틸)-ｎ-(2-하이드록시페닐)-피페리딘-4-카복사마이드 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 프리온 질환 예방 및 치료용 약학적 조성물
CN112126060B (zh) * 2019-06-25 2022-05-31 北京天罡助剂有限责任公司 一种聚合型高分子空间位阻胺及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590231A (en) * 1983-10-11 1986-05-20 Ciba-Geigy Corporation Polyolefin compositions stabilized against degradation using hydroxylamine derivatives
US4665185A (en) * 1984-03-22 1987-05-12 Ciba-Geigy Corporation Process for preparing nitroxyls of sterically hindered amines
US4691015A (en) * 1984-07-23 1987-09-01 Ciba-Geigy Corporation Hydroxylamines derived from hindered amines
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5036097A (en) * 1989-10-17 1991-07-30 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration
CA2072934C (en) * 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5696109A (en) * 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
HUT75469A (en) * 1994-02-28 1997-05-28 Medinova Med Consulting Gmbh Drug targeting system, method for preparing same and its use
DE59504622D1 (de) * 1994-10-31 1999-02-04 Merck Patent Gmbh Benzylpiperidinderivate mit hoher Affinität zu Bindungsstellen von Aminosäure-Rezeptoren
ATE194596T1 (de) * 1994-11-15 2000-07-15 Moreno Paolini N-hydroxypiperidine als superoxid-radikalfänger
US6420429B1 (en) * 1997-12-23 2002-07-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Brain targeted low molecular weight hydrophobic antioxidant compounds
EP1132085A4 (en) * 1998-11-25 2003-04-23 Daiichi Radioisotope Lab MEDICINAL PRODUCTS AND REAGENTS CONTAIN THE N-ACYLOXYLATED CYCLOALKYL COMPOUNDS AS ACTIVE INGREDIENTS
EP1326603A1 (en) 2000-10-05 2003-07-16 Pharmacia Corporation Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension
WO2002058686A2 (en) 2001-01-26 2002-08-01 Metaphore Pharmaceuticals, Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
US20050065182A1 (en) * 2003-09-23 2005-03-24 Papazoglou Elisabeth S. Method and compositions for chronic wound care
WO2005032479A2 (en) * 2003-10-01 2005-04-14 Unviversity Of Florida Research Foundation, Inc. Compositions and methods for selective inhibition of nicotine acetylcholine receptors

Also Published As

Publication number Publication date
US8461186B2 (en) 2013-06-11
RU2377986C2 (ru) 2010-01-10
WO2005084677A1 (en) 2005-09-15
PL1727545T3 (pl) 2013-01-31
US20070191427A1 (en) 2007-08-16
AU2005218739A1 (en) 2005-09-15
RU2006134643A (ru) 2008-04-10
CA2556383A1 (en) 2005-09-15
CN1946400B (zh) 2012-05-09
EP1727545A1 (en) 2006-12-06
EP1727545B1 (en) 2012-08-08
BRPI0507817A (pt) 2007-07-10
KR20060132746A (ko) 2006-12-21
CN1946400A (zh) 2007-04-11
CA2556383C (en) 2013-05-14
NO20064426L (no) 2006-11-29
JP2007525530A (ja) 2007-09-06
ES2392846T3 (es) 2012-12-14
KR101244799B1 (ko) 2013-03-18

Similar Documents

Publication Publication Date Title
SI3424932T1 (sl) Boronoftalidi za terapevtsko uporabo
CR8642A (es) Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
EP1597276A4 (en) Therapeutic molecules
ATE525088T1 (de) Kombinationstherapie
EP1962961A4 (en) HALF-BODY: THERAPEUTIC AGENTS ACTIVATED BY DIMÉRIZATION
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
IS8550A (is) Imídasól efnasambönd til meðhöndlunar á taugahrörnunarsjúkdómum
NO20070251A (no) Brønnbehandling
NO20070297A (no) Brønnbehandling
IL180078A (en) Derivatives of 9-cis retinal for use in treating deficiency of 11-cis retinal
IL184934A0 (en) 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases
ATE407927T1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
PL1708991T3 (pl) Pochodne sulfonoamidu do leczenia chorób
CY2018006I2 (el) Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
DK1885380T3 (da) Natriummetaarsenit til anvendelse til behandling af metastatiske neoplastiske sygdomme
DE602006013636D1 (de) Dosiszähler
IS7444A (is) Morfólínýl-þvagefna afleiður til notkunar við meðhöndlun á bólguvaldandi sjúkdómum
HRP20150320T1 (xx) Formulacije i metode za lijeäśenje amiloidoze
BRPI0821026A2 (pt) Derivados de alfa-minoamidas úteis no tratamento de transtornos psiquiátricos
DE602006004713D1 (de) Trifluormethylbenzamidderivate und therapeutische verwendungen dafür
IL177455A0 (en) Pyrazoline derivatives useful for the treatment of cancer
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.
PL1727545T3 (pl) Zastosowanie pochodnych N-piperydyny do leczenia patologii neurodegeneracyjnych
FI20040180L (fi) Koostumus psoriasis-taudin hoitamiseksi